Wavegate Corporation Announces $26 Million Series A Funding Round Led by UCEA Capital Partners Ltd.

LAKE CHARLES, La., Dec. 10, 2024 /PRNewswire/ — Wavegate Corporation, a pioneering developer of neuromodulation technology for chronic pain management, has secured a lead investor in their $26 million Series A funding round led by UCEA Capital Partners Ltd., a London-based investment firm. This financing will accelerate the development of Wavegate’s proprietary Ellipse platform, featuring StimuLux technology, designed to provide breakthrough therapeutic solutions for chronic pain patients.

Wavegate Corporation has secured led investor UCEA Capital Partners Ltd. for its $26 million Series A funding round

Wavegate’s Ellipse spinal cord stimulator uses optical reflectometry to provide closed-loop adaptive modulation, uniquely adjusting stimulation in real-time based on spinal cord movement. This technology, which received FDA Breakthrough Device designation, offers significant potential to improve the lives of chronic pain sufferers by maintaining consistent pain relief across a range of patient activities using either paresthesia-based or paresthesia-free neuromodulation. Wavegate also recently achieved successful first-in-human data, further validating the clinical promise of its Ellipse platform.

“Securing this funding represents a pivotal moment for Wavegate as we continue to push the boundaries in neuromodulation technology,” said Dr. Erich Wolf, CEO of Wavegate Corporation. “UCEA’s investment validates the potential of our innovations and supports our vision of advancing effective, patient-centered pain management solutions.”

The investment by UCEA Capital Partners aligns with its strategic focus on supporting transformative healthcare technologies. “Wavegate’s approach to neuromodulation reflects exactly the type of high-impact, innovation-driven opportunity we seek to champion. We are thrilled to support their journey in addressing a critical area of unmet medical need,” noted Joao Teixeira, Chairman of UCEA Capital Partners Ltd.

The Series A funding will be instrumental in expanding Wavegate’s R&D efforts, clinical trials, and preparations for regulatory approvals, marking a significant step forward for the company as it progresses toward commercialization.

For more information on Wavegate Corporation, visit wavegate.us.

Media Contact:
Marla Miller, JD, LLM
Corporate Secretary
marla@wavegate.us
+1-337-419-1360

View original content to download multimedia:https://www.prnewswire.com/news-releases/wavegate-corporation-announces-26-million-series-a-funding-round-led-by-ucea-capital-partners-ltd-302328197.html

SOURCE Wavegate Corporation

Staff

Recent Posts

PreveCeutical Announces Up-Sized Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - April 14, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB:…

7 hours ago

10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell…

11 hours ago

Lifetech Resources CEO Shaffiq Rahim Delivers Keynote at 2025 Moorpark Chamber of Commerce Momentum and Impact Dinner

MOORPARK, Calif., April 14, 2025 /PRNewswire/ -- Lifetech Resources is proud to announce that its…

11 hours ago

BlackDoctor.org Appoints Akinwole (Aki) Garrett as President & COO to Lead Next Phase of Growth

CHICAGO, April 14, 2025 /PRNewswire/ -- BlackDoctor.org (BDO), the nation's leading health and wellness destination…

11 hours ago

ACR Statement on JAMA CT Scan Radiation Study (Smith-Bindman, et al)

RESTON, Va., April 14, 2025 /PRNewswire/ -- The theoretical radiation risk proposed by Smith-Bindman, et…

11 hours ago

Minutes of IMPLANET’s Annual General Meeting Held on April 11, 2025

BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext Growth : ALIMP, FR0013470168, éligible PEA-PME), a…

14 hours ago